-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CiIFjfwgChGkLyauC2j7QSFmnAuGMesFL8Fd25O2ypmnHSmb2J9+mTZcq1+nRBUW
 gHovFKh0aq827LE3zi1LDw==

<SEC-DOCUMENT>0001299933-08-003271.txt : 20080702
<SEC-HEADER>0001299933-08-003271.hdr.sgml : 20080702
<ACCEPTANCE-DATETIME>20080702170623
ACCESSION NUMBER:		0001299933-08-003271
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080702
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080702
DATE AS OF CHANGE:		20080702

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		08935321

	BUSINESS ADDRESS:	
		STREET 1:		6400 SOUTH FIDDLER
		STREET 2:		SUITE 1750
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80111
		BUSINESS PHONE:		720-488-1711

	MAIL ADDRESS:	
		STREET 1:		6400 SOUTH FIDDLER
		STREET 2:		SUITE 1750
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_27927.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Lifevantage Corporation (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	July 2, 2008
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Lifevantage Corporation
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Colorado
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	000-30489
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	90-0224471
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	6400 S. Fiddler's Green Circle, Suite 1970, Greenwood Village, Colorado
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	80111
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	720-488-1711
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 7.01 Regulation FD Disclosure.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On July 2, 2008, Lifevantage Corporation sent a letter to its shareholders from its President and Chief Executive Officer, David Brown.  The shareholder letter is attached as Exhibit 99.1 hereto, which is furnished under Item 7.01 of this report and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.<br><br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
Shareholder Letter dated July 2, 2008.<br><br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Lifevantage Corporation
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	July 2, 2008
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	/s/ Bradford K. Amman
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Bradford K. Amman
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Chief Financial Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Shareholder Letter dated July 2, 2008
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">Dear LifeVantage Shareholders:
</FONT>

<P align="left" style="font-size: 12pt">As we begin fiscal year 2009, I want to take this opportunity to thank you for your continued
support and interest in LifeVantage Corporation. I am pleased to share that there have been
significant strides made in strengthening the Company since my tenure began in mid-January, and I
want to take this opportunity to provide you with an update on the recent Company&#146;s activities. In
addition, I would like to provide you with an overview of the strategic direction of LifeVantage.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">I.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Strengthened Management Team.</U></TD>
</TR>

</TABLE>



<P align="left" style="margin-left:6%; font-size: 12pt">With the addition of Jan Strode in Public Relations, Peter Baloff in Marketing, and Ben
Seeman in Sales, the Company now has a team of experienced industry veterans with a
proven track record of building successful companies in the nutraceuticals arena. Each
of these executives have accomplished notable achievements in a short period of time and
a summary of their activities is presented below.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Public Relations Activities.</U></TD>
</TR>

</TABLE>



<P align="left" style="margin-left:8%; font-size: 12pt">Jan Strode has been devoting her time to educating and re-acquainting regional and
national media outlets with the Protandim<FONT style="font-family: Symbol">&#226;</FONT> story. She recently completed a
week long national media tour in New York, meeting with editors and television
producers to discuss Protandim<FONT style="font-family: Symbol">&#226;</FONT> story ideas. The most common question raised
by reporters is in regard to what has happened with the Company and the product
since the 2005 ABC PrimeTime coverage. The media is greatly interested in the
corporate changes the Company has recently undergone, as well as the ongoing product
research.



<P align="left" style="margin-left:8%; font-size: 12pt">Recently, we have received positive feedback from two major media outlets regarding
their desire to do stories in the near future on the Company. Additionally, we are
finalizing details on a regional television news story to be produced by the San
Diego Fox network affiliate. Other stories are in the pipeline and we will keep you
apprised as they develop. Jan and I have scheduled meetings in August to meet with
a number of magazines and other media outlets that will further increase the public
relations momentum.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Marketing Initiatives.</U></TD>
</TR>

</TABLE>



<P align="left" style="margin-left:8%; font-size: 12pt">We have also been extremely busy in the marketing arena. Under the direction of
Peter Baloff, we have developed three direct response television commercials. They
are available for viewing at the Company&#146;s corporate website,
<U>www.Lifevantage.com</U>, under the Investor Information tab. These commercials
first aired as part of a media test in May. That test provided increased exposure,
which led to more sales from inbound calls and greater traffic to the Company&#146;s
product website. It also provided important information that led to revisions to the
commercials, as well as to the choice of networks where commercials will air. We
are currently running a second test, that will continue through the month of July
and which is already proving the wisdom of those changes.



<P align="left" style="margin-left:8%; font-size: 12pt">I invite all of you to visit the Protandim<FONT style="font-family: Symbol">&#226;</FONT> website
(<U>www.protandim.com</U>) which has been significantly revised and updated. It
went live the last week of June and we have seen a marked increase in sales
conversions as a result. Website traffic is up as a result of our online marketing
initiatives and we are closely monitoring the traffic in order to lower our customer
acquisition costs. E-mail promotions have also been successful and we will continue
to use that tool as an inexpensive way to attract new customers and communicate with
existing customers.



<P align="left" style="margin-left:8%; font-size: 12pt">We have also begun testing the efficacy of radio commercials through a test in
Denver. The spots are designed to not only generate inbound sales calls, but to
increase brand awareness so that we can support retail sales at retailers like GNC
and Vitamin Cottage in the area.



<P align="left" style="margin-left:8%; font-size: 12pt">The Company will continue to strive to aggressively increase brand awareness.
However, marketing expenditures will not be made rashly. Rather, we will continue
to test and measure the efficacy of marketing initiatives in a fiscally responsible
manner.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Sales Update.</U></TD>
</TR>

</TABLE>



<P align="left" style="margin-left:8%; font-size: 12pt">Upon joining the Company, members of our management team discovered that the
Protandim<FONT style="font-family: Symbol">&#226;</FONT> brand image needed to be improved and updated. Such changes
cannot occur overnight, but we are making significant progress and I am pleased
that we have been able to stop the sales erosion the Company had been experiencing,
while establishing a solid foundation for sales growth moving forward.



<P align="left" style="margin-left:8%; font-size: 12pt">To that end, we have been moving aggressively to strengthen our relations with
existing retailers like GNC. As a result of programs that Ben Seeman has
instituted, I am very optimistic that our sales at GNC will improve significantly.
Ben has already successfully secured some of the most well-respected brokers in the
industry to help increase distribution and sales. These brokers are paid a
percentage of sales and normally only work with companies much larger than
LifeVantage, but due to their relationship with Ben, as well as their genuine
excitement about the product, they are moving forward rapidly to get the product
into additional natural products outlets.



<P align="left" style="margin-left:8%; font-size: 12pt">On the international front, Nutranomics, Inc., our licensee for Japan, Taiwan and
Hong Kong, reports that the registration process for Japan is moving along well. It
has taken a little longer than originally expected, due to recent additional
requirements imposed by the Japanese government, but we expect formal governmental
approval to issue in the near future. Negotiations with Japanese companies
interested in buying Protandim<FONT style="font-family: Symbol">&#226;</FONT> continue in anticipation of receiving
governmental approval and interest in the product remains strong. Additionally, the
Company is in talks with several other companies interested in licensing, brokering
or distributing the product internationally.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">II.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Science and Research Activities.</U></TD>
</TR>

</TABLE>



<P align="left" style="margin-left:6%; font-size: 12pt">More than 20 scientific studies utilizing Protandim<FONT style="font-family: Symbol">&#226;</FONT> are underway, due to the
product&#146;s proven ability to decrease oxidative stress and the known link between
oxidative stress and the various diseases and conditions being studied.



<P align="left" style="margin-left:6%; font-size: 12pt">Recently, the Company was notified of the completion of two major studies at well-known
institutions. The results were extremely positive, which has led the researchers in
each case to submit their findings to prestigious journals for publication. We will
have more details to report regarding these studies in the next few months.
Additionally, two new studies utilizing the product have been approved and are about to
get underway. Finally, the Company has been asked to participate in a landmark,
large-scale study that will measure not only TBARS, but other significant markers of
oxidative stress.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">III.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Operations.</U></TD>
</TR>

</TABLE>



<P align="left" style="margin-left:6%; font-size: 12pt">The Company intends to move most of its manufacturing requirements to Cornerstone
Research and Development, Inc., a subsidiary of Mitsui Corporation. This will allow us
to achieve a significant reduction in our cost of goods. Cornerstone is well-known in
the industry and will also provide great assistance in future product development
efforts.



<P align="left" style="margin-left:6%; font-size: 12pt">Another significant operational announcement is that the Company will move its corporate
headquarters from Denver to San Diego, California, effective August 1. This move will
not only increase the effectiveness of senior management, most of whom reside in
Southern California, but will give the Company a fresh look in an area well-known for
medical and bio-tech research and development.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">IV.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Product Development.</U></TD>
</TR>

</TABLE>



<P align="left" style="margin-left:6%; font-size: 12pt">The Company recently announced exciting news about a revolutionary skin care system that
it has been developing using the ingredients found in Protandim<FONT style="font-family: Symbol">&#226;</FONT>, together with
other ingredients proven to be effective in diminishing fine line wrinkles, age spots
and other signs of aging in the skin. The products will be tested in a clinical setting
under direction of Dr.&nbsp;Kimberly Stone, a Denver area dermatologist. The study will
commence this month and we are optimistic that positive results will be reported. The
study will continue for 60&nbsp;days and, if earlier preliminary results are duplicated, will
lead to the introduction of two exciting new products in the fall.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">V.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Future Activities.</U></TD>
</TR>

</TABLE>



<P align="left" style="margin-left:6%; font-size: 12pt">With all of this activity, you can see why I am so excited about the Company&#146;s prospects
for this new fiscal year. At retail, we are concentrating on improving product movement
on a per store basis and increasing our current penetration of approximately 3,000
retail outlets to a significantly larger percentage of the approximately 10,000 points
of sale in the natural products retail industry. In addition, we are moving forward to
make the product available through health care practitioners such as chiropractors,
naturopaths and others. That market could add an additional 60,000 points of sale. There
is also interest among medical practitioners such a dermatologists, as well as from
independent pharmacies, health clubs and spas. I am confident we will make significant
in-roads into each of these markets.



<P align="left" style="margin-left:6%; font-size: 12pt">As for our direct marketing efforts, I am pleased that we are driving more unique
visitors to our website and converting more of them into customers. We will continue
those efforts, even as we continue to strive to increase the length of time a customer
remains with us.



<P align="left" style="margin-left:6%; font-size: 12pt">Other initiatives, such as international licensing and new product development will also
continue, with a consistent emphasis on building the brand.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">VI.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Final Thoughts.</U></TD>
</TR>

</TABLE>



<P align="left" style="margin-left:6%; font-size: 12pt">I was initially attracted to LifeVantage Corporation because Protandim<FONT style="font-family: Symbol">&#226;</FONT> is, in my
opinion, unlike any product I have seen in my many years in the industry. Regardless of
any anti-aging properties, Protandim<FONT style="font-family: Symbol">&#226;</FONT> can undoubtedly improve our quality of life
during the time that we do have. I can unequivocally state that everyone should take
this product, which leads to a very large market!



<P align="left" style="margin-left:6%; font-size: 12pt">I want you to know that my team and I do not take lightly our duty to maximize
shareholder value. That is why we are establishing the fundamental basis necessary for
sustained growth and long-term value. We will not just &#147;swing for the fences&#148; and hope
we hit a home-run. Rather, we are utilizing proven sales and marketing techniques that
we believe will result, not only in increased brand recognition, but increased sales and
profitability.



<P align="left" style="margin-left:4%; font-size: 12pt; text-indent: 2%">I have great optimism for the future and look forward to the ride together.



<P align="left" style="margin-left:6%; font-size: 12pt">Sincerely,



<P align="left" style="margin-left:6%; font-size: 12pt">David W. Brown



<P align="left" style="margin-left:6%; font-size: 12pt">President/CEO


<P align="left" style="font-size: 12pt"><FONT style="font-size: 10pt"><I>This letter to shareholders contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on the Company&#146;s current expectations and beliefs concerning future events
affecting the Company and involve known and unknown risks and uncertainties including the risk that
sales of our product may not continue at the levels discussed in this letter. These risks and
uncertainties may cause the Company&#146;s actual results or outcomes to be materially different from
those anticipated and discussed herein. These and other risk factors are discussed in greater
detail in the Company&#146;s Annual Report on </I><I>Form 10-KSB</I><I> for the year ended June&nbsp;30, 2007, and in other
documents filed by the Company from time to time with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the forward-looking statements contained
in this letter. All forward-looking statements are based on information currently available to the
Company, and the Company undertakes no obligation to revise or update these forward-looking
statements.</I>
</FONT>


<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
